MA46752A - Traitement de maladies du snc au moyen de stimulateurs de gcs - Google Patents
Traitement de maladies du snc au moyen de stimulateurs de gcsInfo
- Publication number
- MA46752A MA46752A MA046752A MA46752A MA46752A MA 46752 A MA46752 A MA 46752A MA 046752 A MA046752 A MA 046752A MA 46752 A MA46752 A MA 46752A MA 46752 A MA46752 A MA 46752A
- Authority
- MA
- Morocco
- Prior art keywords
- gcs
- stimulators
- treatment
- cns diseases
- cns
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
- A61K31/437—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a five-membered ring having nitrogen as a ring hetero atom, e.g. indolizine, beta-carboline
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/50—Pyridazines; Hydrogenated pyridazines
- A61K31/5025—Pyridazines; Hydrogenated pyridazines ortho- or peri-condensed with heterocyclic ring systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
- A61P25/16—Anti-Parkinson drugs
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Epidemiology (AREA)
- Biomedical Technology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Neurology (AREA)
- Neurosurgery (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Organic Chemistry (AREA)
- Hospice & Palliative Care (AREA)
- Psychiatry (AREA)
- Psychology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201662419059P | 2016-11-08 | 2016-11-08 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| MA46752A true MA46752A (fr) | 2019-09-18 |
Family
ID=60452769
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| MA046752A MA46752A (fr) | 2016-11-08 | 2017-11-07 | Traitement de maladies du snc au moyen de stimulateurs de gcs |
Country Status (19)
| Country | Link |
|---|---|
| US (4) | US11690828B2 (fr) |
| EP (1) | EP3538096B1 (fr) |
| JP (2) | JP7150740B2 (fr) |
| KR (1) | KR102475124B1 (fr) |
| CN (1) | CN110267658B (fr) |
| AU (2) | AU2017359018C1 (fr) |
| BR (1) | BR112019009449A2 (fr) |
| CA (1) | CA3042548A1 (fr) |
| CL (1) | CL2019001256A1 (fr) |
| EA (1) | EA201991147A1 (fr) |
| ES (1) | ES2972711T3 (fr) |
| IL (1) | IL266275B2 (fr) |
| MA (1) | MA46752A (fr) |
| MX (2) | MX2019005342A (fr) |
| NZ (1) | NZ753434A (fr) |
| PH (1) | PH12019501016A1 (fr) |
| SG (1) | SG10202104865UA (fr) |
| TW (1) | TWI812601B (fr) |
| WO (1) | WO2018089328A1 (fr) |
Families Citing this family (9)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US11180493B2 (en) * | 2016-11-08 | 2021-11-23 | Cyclerion Therapeutics, Inc. | SGC stimulators |
| WO2019055859A1 (fr) * | 2017-09-14 | 2019-03-21 | Ironwood Pharmaceuticals, Inc. | Traitement du syndrome métabolique par des un stimulateur de sgc |
| SG11202100092QA (en) | 2018-07-11 | 2021-02-25 | Cyclerion Therapeutics Inc | USE OF sGC STIMULATORS FOR THE TREATMENT OF MITOCHONRIAL DISORDERS |
| US20220087970A1 (en) * | 2019-01-18 | 2022-03-24 | The Johns Hopkins University | Prevention of anesthetic-induced neurocognitive dysfunction |
| CN114929207A (zh) * | 2019-12-05 | 2022-08-19 | 载度思生命科学有限公司 | 利奥西呱的调节释放型药物组合物 |
| CN119139297A (zh) | 2020-02-07 | 2024-12-17 | 株式会社纽若梵提 | 包含利美尼定的组合物的应用 |
| CN112924573B (zh) * | 2021-01-21 | 2022-01-04 | 山东英盛生物技术有限公司 | 一种阿比多尔、利巴韦林、氯喹的hplc-ms/ms检测方法 |
| US20250064799A1 (en) * | 2021-12-31 | 2025-02-27 | Tenax Therapeutics, Inc. | Oral formulations of levosimendan for treating pulmonary hypertension with heart failure with preserved ejection fraction |
| KR20250160137A (ko) * | 2023-02-03 | 2025-11-11 | 알.피.쉐러 테크놀러지즈 엘엘씨 | 삼투압 약학적 캡슐 |
Family Cites Families (36)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US3773919A (en) | 1969-10-23 | 1973-11-20 | Du Pont | Polylactide-drug mixtures |
| US3995631A (en) | 1971-01-13 | 1976-12-07 | Alza Corporation | Osmotic dispenser with means for dispensing active agent responsive to osmotic gradient |
| US4203440A (en) | 1978-10-23 | 1980-05-20 | Alza Corporation | Device having variable volume chamber for dispensing useful agent |
| US4627850A (en) | 1983-11-02 | 1986-12-09 | Alza Corporation | Osmotic capsule |
| EP0192963B1 (fr) | 1985-02-27 | 1988-07-20 | Werkzeugmaschinenfabrik Oerlikon-Bührle AG | Installation de mesure des vibrations d'une transmission à roues coniques dentées en spirale sur une machine d'essai de roues dentées |
| IL92966A (en) | 1989-01-12 | 1995-07-31 | Pfizer | Dispensing devices powered by hydrogel |
| US5304121A (en) | 1990-12-28 | 1994-04-19 | Boston Scientific Corporation | Drug delivery system making use of a hydrogel polymer coating |
| US5324280A (en) | 1990-04-02 | 1994-06-28 | Alza Corporation | Osmotic dosage system for delivering a formulation comprising liquid carrier and drug |
| US5886026A (en) | 1993-07-19 | 1999-03-23 | Angiotech Pharmaceuticals Inc. | Anti-angiogenic compositions and methods of use |
| JP2928079B2 (ja) | 1994-02-14 | 1999-07-28 | 永信薬品工業股▲ふん▼有限公司 | １−（置換ベンジル）−３−（置換アリール）縮合ピラゾール類、その製造法及びその用途 |
| US6099562A (en) | 1996-06-13 | 2000-08-08 | Schneider (Usa) Inc. | Drug coating with topcoat |
| DE19744026A1 (de) | 1997-10-06 | 1999-04-08 | Hoechst Marion Roussel De Gmbh | Pyrazol-Derivate, ihre Herstellung und ihre Verwendung in Arzneimitteln |
| PL199236B1 (pl) | 1998-07-08 | 2008-08-29 | Sanofi Aventis Deutschland | N-Aryloamidy kwasów sulfonyloaminokarboksylowych podstawionych siarką, sposób ich wytwarzania, środek farmaceutyczny i zastosowanie N-aryloamidów kwasów sulfonyloaminokarboksylowych podstawionych siarką |
| DE19830430A1 (de) | 1998-07-08 | 2000-01-13 | Hoechst Marion Roussel De Gmbh | Schwefelsubstituierte Sulfonylamino-carbonsäure-N-arylamide, ihre Herstellung, ihre Verwendung und sie enthaltende pharmazeutische Präparate |
| DE19834047A1 (de) | 1998-07-29 | 2000-02-03 | Bayer Ag | Substituierte Pyrazolderivate |
| DE19834044A1 (de) | 1998-07-29 | 2000-02-03 | Bayer Ag | Neue substituierte Pyrazolderivate |
| GB9824310D0 (en) | 1998-11-05 | 1998-12-30 | Univ London | Activators of soluble guanylate cyclase |
| MXPA01006108A (es) | 1998-12-17 | 2002-09-18 | Alza Corp | Conversion de capsulas de gelatina rellenas de liquido en sistemas de liberacion controlada mediante multiples recubrimientos. |
| US6342249B1 (en) | 1998-12-23 | 2002-01-29 | Alza Corporation | Controlled release liquid active agent formulation dosage forms |
| DE19942809A1 (de) | 1999-09-08 | 2001-03-15 | Bayer Ag | Verfahren zur Herstellung substituierter Pyrimidinderivate |
| DE19943635A1 (de) | 1999-09-13 | 2001-03-15 | Bayer Ag | Neuartige Aminodicarbonsäurederivate mit pharmazeutischen Eigenschaften |
| DE10216145A1 (de) | 2002-04-12 | 2003-10-23 | Bayer Ag | Verwendung von Stimulatoren der löslichen Guanylatcyclase zur Behandlung von Glaukom |
| DE10220570A1 (de) | 2002-05-08 | 2003-11-20 | Bayer Ag | Carbamat-substituierte Pyrazolopyridine |
| MXPA06001506A (es) | 2003-08-04 | 2006-05-15 | Pfizer Prod Inc | Formas de dosificacion de inhibidores de la proteina de transferencia de colesteril ester e inhibidores de la hmg-coa reductasa. |
| DE102006020327A1 (de) * | 2006-04-27 | 2007-12-27 | Bayer Healthcare Ag | Heterocyclisch substituierte, anellierte Pyrazol-Derivate und ihre Verwendung |
| CN101939053A (zh) | 2007-09-06 | 2011-01-05 | 默沙东公司 | 可溶性的鸟苷酸环化酶活化剂 |
| WO2009094242A1 (fr) | 2008-01-24 | 2009-07-30 | Merck & Co., Inc. | Antagonistes du récepteur de l'angiotensine ii |
| WO2010065275A1 (fr) | 2008-11-25 | 2010-06-10 | Merck Sharp & Dohme Corp. | Activateurs de guanylate cyclase soluble |
| EP2401265B1 (fr) | 2009-02-26 | 2016-09-14 | Merck Sharp & Dohme Corp. | Derives d'acide 1-pyri(mid)in-2-yl-pyrazole-4-carboxylique utiles dans la therapie ou la prophylaxie de maladies cardiovasculaires |
| EP2549875B1 (fr) | 2010-03-25 | 2015-05-13 | Merck Sharp & Dohme Corp. | Activateurs de guanylate cyclase solubles |
| EP2575473B1 (fr) | 2010-05-27 | 2016-01-20 | Merck Sharp & Dohme Corp. | Activateurs de guanylate cyclase soluble |
| EP2632551B1 (fr) | 2010-10-28 | 2016-07-06 | Merck Sharp & Dohme Corp. | Activateurs de la guanylate cyclase soluble |
| CA3006764A1 (fr) * | 2015-12-14 | 2017-06-22 | Ironwood Pharmaceuticals, Inc. | Utilisation de stimulateurs de la sgc pour le traitement d'un dysfonctionnement du sphincter gastro-intestinal |
| WO2017108441A1 (fr) | 2015-12-22 | 2017-06-29 | Universiteit Maastricht | Traitement de la déficience cognitive à l'aide d'un stimulateur de la sgc |
| WO2017121700A1 (fr) | 2016-01-15 | 2017-07-20 | Bayer Pharma Aktiengesellschaft | Dérivés de 1h-pyrazolo[3,4-b]pyridine 1,3-disubstitués et leur utilisation en tant que stimulateurs de la guanylacte cyclase soluble |
| MY199759A (en) * | 2016-09-02 | 2023-11-21 | Tisento Therapeutics Inc | Fused bicyclic sgc stimulators |
-
2017
- 2017-11-07 SG SG10202104865UA patent/SG10202104865UA/en unknown
- 2017-11-07 JP JP2019545723A patent/JP7150740B2/ja active Active
- 2017-11-07 IL IL266275A patent/IL266275B2/en unknown
- 2017-11-07 MX MX2019005342A patent/MX2019005342A/es unknown
- 2017-11-07 TW TW106138467A patent/TWI812601B/zh active
- 2017-11-07 MA MA046752A patent/MA46752A/fr unknown
- 2017-11-07 US US16/348,359 patent/US11690828B2/en active Active
- 2017-11-07 NZ NZ753434A patent/NZ753434A/en unknown
- 2017-11-07 KR KR1020197016351A patent/KR102475124B1/ko active Active
- 2017-11-07 CA CA3042548A patent/CA3042548A1/fr active Pending
- 2017-11-07 ES ES17804374T patent/ES2972711T3/es active Active
- 2017-11-07 BR BR112019009449A patent/BR112019009449A2/pt not_active IP Right Cessation
- 2017-11-07 WO PCT/US2017/060299 patent/WO2018089328A1/fr not_active Ceased
- 2017-11-07 CN CN201780080543.0A patent/CN110267658B/zh active Active
- 2017-11-07 AU AU2017359018A patent/AU2017359018C1/en active Active
- 2017-11-07 EP EP17804374.1A patent/EP3538096B1/fr active Active
- 2017-11-07 EA EA201991147A patent/EA201991147A1/ru unknown
-
2019
- 2019-05-07 CL CL2019001256A patent/CL2019001256A1/es unknown
- 2019-05-07 MX MX2022010852A patent/MX2022010852A/es unknown
- 2019-05-08 PH PH12019501016A patent/PH12019501016A1/en unknown
-
2022
- 2022-08-08 JP JP2022126467A patent/JP2022160605A/ja active Pending
-
2023
- 2023-05-12 US US18/196,826 patent/US20230381153A1/en not_active Abandoned
- 2023-11-22 AU AU2023270267A patent/AU2023270267A1/en not_active Abandoned
-
2024
- 2024-07-31 US US18/790,576 patent/US20250108040A1/en not_active Abandoned
- 2024-12-18 US US18/986,454 patent/US20260000653A1/en active Pending
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| MA46752A (fr) | Traitement de maladies du snc au moyen de stimulateurs de gcs | |
| EP3548039A4 (fr) | Méthodes de traitement de maladies associées au stress mitochondrial | |
| MA47095A (fr) | Traitement du palais mou | |
| EP3389725A4 (fr) | Compositions et méthodes pour le traitement de maladies du système nerveux central | |
| EP3448875A4 (fr) | Compositions pour le traitement de maladies | |
| EP3448987A4 (fr) | Compositions pour le traitement de maladies | |
| EP3390634A4 (fr) | Compositions et méthodes pour le traitement de maladies oculaires | |
| EP3875139C0 (fr) | Traitement des maladies veineuses | |
| EP3720553C0 (fr) | Dispositif de photobiomodulation destiné au traitement d'une maladie rétinienne | |
| EP3454945A4 (fr) | Inhibiteurs de ash1l et méthodes de traitement au moyen de ceux-ci | |
| EP3658139A4 (fr) | Méthodes de traitement de maladies hépatiques | |
| EP3370703A4 (fr) | Combinaison de gemcabène pour le traitement de maladies cardiovasculaires | |
| EP3634442A4 (fr) | Méthodes de traitement et de prévention de maladies | |
| FR25C1031I1 (fr) | Traitement de maladies cholestatiques intrahepatiques | |
| EP3448263A4 (fr) | Traitement électrothérapeutique | |
| EP2975055A4 (fr) | Anticorps anti-c5 et méthode de prévention et de traitement de maladies liées au complément | |
| EP3390666A4 (fr) | Compositions et méthodes de traitement de maladies rénales | |
| EP3273955A4 (fr) | Traitement de maladies respiratoires | |
| EA201890185A1 (ru) | Способы лечения опосредованных гепсидином нарушений | |
| MA48996A (fr) | Méthodes de traitement de maladies neurodégénératives | |
| EP3373962A4 (fr) | Compositions et méthodes de traitement de maladies auto-immunes et de cancers | |
| EP3294274A4 (fr) | Traitement de maladies du snc avec des cellules inductibles encapsulées de plexus choroïdes | |
| MA42930A (fr) | Traitement de maladies neurodégénératives | |
| EP3364974A4 (fr) | Modulateurs de maladies impliquant des télomères | |
| DK3104852T3 (da) | Sammensætninger og fremgangsmåde til behandling af aldring og aldersbetingede sygdomme og symptomer |